Table 2.

Characteristics of patients with GCA according to whether they relapsed.

CharacteristicsRelapsing Patients, n = 171Nonrelapsing Patients, n = 155p
Demographics
  Female128 (75)111 (72)0.51
  Age, yrs74 (53–89)76 (48–92)0.09
Cardiovascular risk factors
  Tobacco use31 (18)26 (17)0.75
  Hypertension87 (51)84 (54)0.55
  Dyslipidemia50 (29)53 (34)0.34
  Diabetes mellitus15 (9)19 (12)0.30
  History of coronary disease14 (8)10 (6)0.55
  History of stroke7 (4)18 (12)0.01
Clinical manifestations
  BMI25 (16–37)25 (16–36)0.20
  Fever38 (22)28 (18)0.35
  Cranial manifestations152 (89)145 (94)0.14
  Headaches136 (80)134 (86)0.1
  Scalp tenderness75 (44)66 (43)0.82
  Jaw claudication69 (40)64 (41)0.87
  Ophthalmic trouble38 (22)41 (26)0.37
  Temporal pulse absence38 (22)40 (26)0.45
  Limb claudication9 (5)6 (4)0.55
  Polymyalgia rheumatica92 (54)73 (47)0.23
Laboratory tests
  ESR, mm68 (7–138)66 (7–138)0.71
  CRP, mg/l78 (3–398)70 (3–424)0.40
  Hemoglobin, g/dl11.2 (7.4–14.7)11.5 (8.5–15.3)0.15
  Platelets, g/mm3404 (140–772)439 (196–785)0.46
Positive histology105 (64)101 (66)0.71
  Positive TAB104 (63)99 (66)0.59
Large-vessel involvement on imaging45/114 (39)22/94 (23)0.01
Treatment
  GC doses, mg/kg
    At onset0.73 (0.25–1.45)0.77 (0.29–1.45)0.09
    At Month 30.35 (0.12–1.04)0.34 (0.14–0.83)0.98
    At Month 60.19 (0.08–0.7)0.175 (0.06–0.65)0.15
    At Month 120.12 (0.02–0.53)0.09 (0.01–0.56)< 0.0001
  Discontinuation of GC95 (56)110 (71)0.004
  Duration of GC treatment, mos29 (10–212)18 (6–156)< 0.0001
Cardiovascular complications29 (18)31 (20)0.48
Death25 (15)24 (15)0.83
  • Values are n (%) or median (range) unless otherwise specified. GCA: giant cell arteritis; CRP: C-reactive protein; BMI: body mass index; ESR: erythrocyte sedimentation rate; TAB: temporal artery biopsy; GC: glucocorticoids.